EULAR/ACR Treatment Guidelines for Polymyalgia Rheumatica

Polymyalgia rheumatica (PMR) treatment varies significantly in glucocorticoid dosages, tapering strategies and DMARD use. Much of these differences are due to a lack of standardized international guidance. Between 29 and 45 percent of patients with polymyalgia rheumatica do not respond sufficiently to treatment with glucocorticoids within four weeks, and relapses are frequent. Side effects also appear in 50 percent of patients.The European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) have published nine treatment recommendations. In this slideshow, we highlight the recommendations.REFERENCEDejaco C, Singh Y, Perel P, Hutchings A, et al. “2015 Recommendations for the Management of Polymyalgia Rheumatica.” Arthritis & Rheumatology (2015) doi: 10.1002/art.39333